scorecardresearch
Thursday, September 11, 2025
TopicFavipiravir

Topic: favipiravir

India’s second wave sees Covid drug FabiFlu sales jump 600% in April to rake in Rs 351 crore

FabiFlu replaced multivitamin drug Zincovit as the top selling drug as India witnessed the highest number of Covid infections, hospitalisations and deaths in April.

What’s on our minds in peak pandemic? ‘Oxygen’, ‘plasma’ and ‘remdesivir’, says Google

Indian social media has been inundated with posts about Covid — from availability or lack of oxygen and hospital beds to treatment options. What an analysis of Google Trends found.

Remdesivir, favipiravir sales zoom to record Rs 1,000 crore in 7 months in Covid year

Indian pharma industry launched 44 new antiviral brands in 2020, against just 10 such launches in 2019. However, total number of new brands saw 40% decline.

Modi govt panel rejects proposal to make chewable Favipiravir tablets for Covid patients

Committee didn’t find MacLeods Pharma’s proposal adequate, but is considering US firm Mylan’s proposal to test Favipiravir with three other drugs.

Test efficacy of umifenovir alone as Covid drug, not with favipiravir — govt panel to Macleods

Mumbai-based Macleods Pharmaceuticals had sought permission to conduct clinical trials on umifenovir, a Russian drug used to treat influenza.

Govt panel rejects Glenmark proposal to test Covid drug favipiravir with steroid dexamethasone

Modi govt's subject expert committee rejects Glenmark's proposal by highlighting that its justifications to conduct trials of favipiravir with dexamethasone were 'not adequate'.

Cipla, Optimus get nod for phase 4 trials to check efficacy of Covid drug favipiravir

Study will note clinical improvement of Covid patients & assess safety of favipiravir. It will also see ‘mortality, disease progression & viral clearance’ at given stages.

Zenara Pharma latest Indian firm to get nod for ‘Covid drug’ favipiravir, to call it Favizen

Touted as a potential Covid treatment, favipiravir tablets to be sold by Zenara Pharma, a subsidiary of Biophore, will be manufactured in Hyderabad.

Covid patients given favipiravir showed ‘40% faster’ recovery, Glenmark trial results claim

Glenmark conducted phase 3 clinical trials of favipiravir on 150 mild to moderate Covid patients. Adverse events, or side effects, reported in 32 patients.

Favipiravir cheapest in India, false claims hurting reputation — Glenmark tells Modi govt

The pharma company came under the scanner after the DCGI sent a letter based on a representation by an MP.

On Camera

Lifting night shift ban increased female employment in India—only among big firms

Discriminatory laws limit firms from hiring willing women, and removing such barriers can help narrow the economic gap between developing and developed countries.

What’s behind bond yields’ logic-defying spike? The market’s concern over the future

While bond yields tend to fall amid low inflation & interest rate cuts, market experts say they’ve been rising due to concerns over tax collections, fiscal deficit & potential impact of US tariffs.

‘Foreign policy rests on hard power’—from 1965 Indo-Pak war to Op Sindoor, key takeaways for India

A panel of experts moderated by ThePrint’s Editor-in-Chief Shekhar Gupta drew connections between insights of 1965 Indo-Pak War and strategic takeaways highlighted by Op Sindoor.

Punjab is fast becoming the new Northeast. And there’s a message in it for Modi

In its toughest time in decades because of floods, Punjab would’ve expected PM Modi to visit. If he has the time for a Bihar tour, why not a short visit to next-door Punjab?